| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
Purity: SDS-PAGE Purity =99.3%
| Targets |
OVA is used as a model allergen/antigen, not a drug targeting a specific molecular target
Ovalbumin does not have a single specific molecular target but interacts with various components of the immune system. It is a well-known model antigen used extensively in immunological research to study antigen processing, presentation, and T-cell responses. As a protein, it is recognized by the immune system and can elicit both humoral and cell-mediated immune responses. It is commonly used as a marker to study hormone regulation of gene expression in tissues. |
|---|---|
| ln Vitro |
In vitro studies of ovalbumin typically involve its use as a model antigen in immunological assays. It is used to stimulate T-cell proliferation and cytokine production in cell culture. The EliCell assay uses ovalbumin as a medium for cell incubation for the detection of released cytokines from eosinophils. It is also used as a marker for protein electrophoresis. The compound's various biological activities, such as antibacterial, anticancer, and antioxidant activities, have been studied in vitro.
|
| ln Vivo |
Ovalbumins (OVA) (Silica nanoparticles): 1 mg/kg, six intranasal injections spread over two weeksSNP/OVA Coadministration of SNP resulted in considerable airway allergic inflammation in the female BALB/c mouse model, which was accompanied by an increase in eosinophils and lymphocytes as well as total cells, macrophages, and neutrophils [1].
In a mouse model of allergic airway inflammation, intranasal administration of ovalbumin (OVA, 1 mg/kg per treatment, six times over 2 weeks) alone (saline/OVA group) did not induce significant airway hyper-responsiveness (AHR), inflammatory cell infiltration in bronchoalveolar lavage fluid (BALF), or pathological changes compared to the control group. [1] When co-administered with silica nanoparticles (SNPs), OVA (1 mg/kg per treatment, six times over 2 weeks) induced significant adjuvant effects, including increased AHR, increased total cell counts (macrophages, lymphocytes, eosinophils, neutrophils) in BALF, peribronchial and perivascular inflammation, goblet cell metaplasia (PAS staining), and elevated levels of cytokines IL-5, IL-13, IL-1β, and IFN-γ in lung homogenates. [1] In vivo, ovalbumin is widely used to induce immune responses in animal models. It is commonly used to produce an animal model of asthma. In this model, animals are sensitized with ovalbumin and then challenged with the antigen to induce airway inflammation and hyperresponsiveness. Ovalbumin is also used in models of food allergy and other immune-mediated diseases. Its immunomodulatory and other biological activities have been studied in vivo. |
| Enzyme Assay |
To evaluate the toxic and adjuvant effects of 3 types of SNPs in the airway system, six-week-old female BALB/c mice were intranasally administered 3 types of SNPs (spherical [S-SNP], mesoporous [M-SNP], and polyethylene glycol-conjugated [P-SNP]) alone or SNPs/ovalbumin (OVA), three times weekly for 2 weeks. Airway hyper-responsiveness (AHR), bronchoalveolar lavage fluid (BALF), cytokine levels, and histology of the lungs were analyzed.
In vitro assays for ovalbumin typically involve its use as a model antigen in immunological assays. Antigen presentation assays use ovalbumin to study the processing and presentation of antigens by antigen-presenting cells. T-cell proliferation assays measure the proliferation of T-cells in response to ovalbumin stimulation. ELISA and other immunoassays use ovalbumin-specific antibodies to detect and quantify the protein. |
| Cell Assay |
In vitro cell-based assays using ovalbumin typically involve the culture of immune cells with the protein to study immune responses. For example, dendritic cells or macrophages are pulsed with ovalbumin to study antigen processing and presentation. T-cells are co-cultured with antigen-presenting cells and ovalbumin to study T-cell activation and proliferation. The EliCell assay uses ovalbumin as a medium for cell incubation.
|
| Animal Protocol |
Female BALB/c mice, 5–6 weeks old, were purchased. SNPs alone and SNP/OVA model were used 5 mice for each group. All mice were maintained at conventional animal facilities under standard conditions (room temperature of 21–24 °C and relative humidity of 45–70 %, with a 12 h light/dark cycle), and all experimental protocols were approved by the Department of Laboratory Animal Resources, Yonsei Biomedical Research institute, Yonsei University College of Medicine. The present study was approved by the guide for the care and use of laboratory animal guide line. SNPs sized 100 nm were administered via intranasal inoculation of 10 mg/kg per treatment (SNP direct toxicity model, Experiment 1, Fig. 2a) and SNPs 10 mg/kg per treatment and OVA 1 mg/kg (SNP/OVA model, Experiment 2, Fig. 2b) were administered 6 times over 2 weeks[1].
Six-week-old female BALB/c mice were used. For the SNP/OVA adjuvant effect model, mice were administered ovalbumin (OVA) at a dose of 1 mg/kg per treatment (EndoFit Ovalbumin, low endotoxin) via intranasal inoculation. OVA was administered together with SNPs (10 mg/kg per treatment) three times weekly for 2 weeks (total of 6 administrations). The saline/OVA group received OVA alone. AHR was measured 48 hours after the last challenge using a forced oscillation technique (FlexiVent) in response to aerosolized methacholine (3.125–50.0 mg/mL). [1] In vivo animal studies using ovalbumin typically involve the induction of immune responses in animal models. The ovalbumin-induced asthma model is one of the most common uses. In this model, mice or rats are sensitized with ovalbumin (often with an adjuvant) and then challenged with ovalbumin via inhalation or intranasal administration to induce airway inflammation. Other models include food allergy and oral tolerance studies. |
| ADME/Pharmacokinetics |
As a protein, ovalbumin has a molecular weight of approximately 45 kDa. It is the main protein found in egg whites. The CAS number is 9006-59-1. The compound is typically supplied as a lyophilized powder and should be stored according to the manufacturer's recommendations. It is soluble in water and buffer solutions.
|
| Toxicity/Toxicokinetics |
In this study, ovalbumin (OVA) alone (saline/OVA group) did not induce significant airway inflammation, AHR, or pathological changes, indicating that at the dose and route used (1 mg/kg, intranasal, six times over 2 weeks), OVA was not toxic to the airway system in the absence of an adjuvant. [1]
The toxicity profile of ovalbumin is well-established, as it is a common food protein. However, it can cause allergic reactions in sensitive individuals. In research settings, ovalbumin is generally considered safe when handled appropriately. It is intended for research use only and is not approved for therapeutic use in humans. Standard laboratory safety practices should be followed when handling this compound. |
| References |
[1]. Toxic and adjuvant effects of silica nanoparticles on ovalbumin-induced allergic airway inflammation in mice. Respir Res. 2016 May 18;17(1):60.
|
| Additional Infomation |
Ovalbumin (OVA) is used in this study as a model allergen to evaluate the adjuvant effects of silica nanoparticles (SNPs) in inducing allergic airway inflammation. OVA alone did not induce allergic airway inflammation, but co-exposure with SNPs significantly enhanced allergic responses, demonstrating that SNPs have an adjuvant effect for OVA sensitization. [1]
Ovalbumin (OVA) (CAS 9006-59-1) is the main protein found in egg whites, synthesized in estrogen- or progesterone-treated fallopian tubes. It has various biological activities such as antibacterial, anticancer, antihypertensive, antioxidant, and immunomodulatory activities. It is useful as a marker (~45 kDa) for protein electrophoresis and has been used to produce an animal model of asthma. |
| CAS # |
9006-59-1
|
|---|---|
| PubChem CID |
3277971
|
| Appearance |
White to light yellow solid
|
| Melting Point |
60°C
|
| LogP |
0.7
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
21
|
| Complexity |
469
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
UOXVFQCRPDLSFN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H26O5/c1-10(2)6-7-12-15(4,21-12)16(19)13(20-5)11(17)8-9-14(16,3)18/h6,12-13,18-19H,7-9H2,1-5H3
|
| Chemical Name |
3,4-dihydroxy-2-methoxy-4-methyl-3-[2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]cyclohexan-1-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :≥ 100 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA